News of Note—Bavarian Nordic, FluGen and more


Here is some other vaccine news of note for the week:

> Bavarian Nordic shipped Imvanex smallpox vaccine doses to England after authorities there recorded monkeypox cases. Release

> The National Institutes of Health is supporting phase 1 testing of a broadly protective flu vaccine developed by FluGen. Release

> Sinovac reports that the U.S. Department of Justice has closed an investigation into the company. Release

> In a preclinical study, an experimental H3N2 flu DNA vaccine from Inovio elicited antibody responses and protected against a heterologous lethal challenge. Release

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.